Free Trial
→ Financial legend: “This is bad, really bad...” (From Weiss Ratings) (Ad)tc pixel
NASDAQ:CGON

CG Oncology Q3 2026 Earnings Date & Estimates

CG Oncology logo
$59.85 -2.01 (-3.25%)
Closing price 10/16/2026 04:00 PM Eastern
Extended Trading
$59.83 -0.02 (-0.03%)
As of 10/16/2026 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CG Oncology is estimated to report Q3 2026 earnings on Friday, November 13, 2026, before market opens. The conference call is scheduled for November 12, 2026 at 12:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
12:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from CG Oncology in Q3 2026

CG Oncology is expected to post earnings of -$0.8341 per share on revenue of $0.55 million. In the same quarter a year earlier CG Oncology reported -$0.57 per share on revenue of $0.16 million. CG Oncology last reported on August 6, 2026, posting -$0.90 per share and missing the -$0.6642 consensus estimate. CG Oncology has beaten the consensus EPS estimate in 2 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.8341
Expected Revenue
$0.55 million
Prior-Year EPS
-$0.57
Prior-Year Revenue
$0.16 million
Expected Revenue Growth
+246.8%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.90 (Missed by -$0.2359)
Last Quarter Revenue
$1.16 million
EPS Beat Rate
2 of last 8 quarters

Prepare for the Q3 2026 Call

CG Oncology Q3 2026 Earnings FAQ

CG Oncology (NASDAQ:CGON) is estimated to report Q3 2026 earnings on Friday, November 13, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

CG Oncology's Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 12:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect CG Oncology to post earnings of -$0.8341 per share for Q3 2026.

The consensus revenue estimate for CG Oncology is $0.55 million for Q3 2026.

CG Oncology Earnings Headlines

CG Oncology, Inc. Appoints Isabel Kalofonos as Chief Commercial Officer
October 13, 2026  |  marketscreener.comM
CG Oncology Inc CGON
October 13, 2026  |  morningstar.comM
Why Some AI Stocks Already Surged Over 300 Percent
Jason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run, and Vertiv before a 1900 percent run. Now he's tracking a radical light-speed technology that could make AI 100 times faster and 100 times more energy efficient. Stocks tied to it have already climbed 133 percent, 217 percent, and 320 percent.tc pixel
October 18 at 1:00 AM  |  Brownstone Research (Ad)
How Investors May Respond To CG Oncology (CGON) Hiring a CCO Before Potential Bladder Cancer Launch
October 13, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/investors-may-respond-cg-oncology-021051609.html
CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial Officer
October 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/13/3379652/0/en/cg-oncology-appoints-proven-biopharmaceutical-commercial-leader-isabel-kalofonos-as-chief-commercial-officer.html
CG Oncology (NASDAQ:CGON) and Myriad Genetics (NASDAQ:MYGN) Head-To-Head Review
October 13, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31114213
See More CG Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CG Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CG Oncology and other key companies, straight to your email.

About CG Oncology

CG Oncology (NASDAQ:CGON) (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on developing therapies for bladder cancer and other cancers of the urinary tract. The company’s research centers on cancer-directed immunotherapies designed to stimulate the immune system and target tumor cells.

Its lead product candidate is cretostimogene grenadenorepvec, an intravesical oncolytic adenovirus being studied for the treatment of non-muscle-invasive bladder cancer (NMIBC). The therapy is designed to be delivered directly into the bladder, where it may selectively infect tumor cells and activate an immune response against cancer.

CG Oncology has evaluated cretostimogene in clinical studies involving patients with NMIBC, including individuals whose disease has not responded adequately to Bacillus Calmette-Guérin (BCG), a standard bladder cancer treatment. The company’s development efforts have included studies of different NMIBC patient populations and treatment settings. CG Oncology is headquartered in California and has focused its operations primarily on advancing its oncology pipeline through clinical development.

View CG Oncology Profile
Earnings Tools